Drug Landscape ›
Epinephrine 1:100,000 ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 441
Most-reported reactions
Drug Ineffective — 367 reports (83.22%) Dizziness — 11 reports (2.49%) Dyspnoea — 10 reports (2.27%) Pain — 10 reports (2.27%) Swelling Face — 8 reports (1.81%) Headache — 7 reports (1.59%) Injection Site Ulcer — 7 reports (1.59%) Palpitations — 7 reports (1.59%) Paraesthesia — 7 reports (1.59%) Vomiting — 7 reports (1.59%)
Source database →
Epinephrine 1:100,000 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Epinephrine 1:100,000 approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Epinephrine 1:100,000 in United States?
Rio de Janeiro State University is the originator. The local marketing authorisation holder may differ — check the official source linked above.